---
title: "$1000 Invested In Novartis 5 Years Ago Would Be Worth This Much Today"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304542586.md"
description: "Novartis (NYSE:NVS) has outperformed the market over the past five years with an annualized return of 15.55%, beating the market by 6.13%. A $1,000 investment made five years ago would now be worth $2,056.29, based on a current share price of $161.50. The company currently holds a market capitalization of $311.59 billion."
datetime: "2026-11-05T23:15:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304542586.md)
  - [en](https://longbridge.com/en/news/304542586.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304542586.md)
generator: "portal-rs"
---

# $1000 Invested In Novartis 5 Years Ago Would Be Worth This Much Today

Novartis (NYSE:NVS) has outperformed the market over the past 5 years by 6.13% on an annualized basis producing an average annual return of 15.55%. Currently, Novartis has a market capitalization of $311.59 billion.

**Buying $1000 In NVS:** If an investor had bought $1000 of NVS stock 5 years ago, it would be worth **$2,056.29** today based on a price of $161.50 for NVS at the time of writing.

### Novartis’s Performance Over Last 5 Years

![comp_fig](https://imageproxy.pbkrs.com/https://cdn.benzinga.com/files/images/story/2026/11/05/e63f8284f6118285c374f1c3ae2d3283.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

Finally -- what’s the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.

*This article was generated by Benzinga's automated content engine and reviewed by an editor.*

### Related Stocks

- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)
- [NOT.DE](https://longbridge.com/en/quote/NOT.DE.md)

## Related News & Research

- [Novartis publishes Q3 impact and sustainability update](https://longbridge.com/en/news/305047961.md)
- [Novartis' Coartem Baby Wins Approval in 16 Countries](https://longbridge.com/en/news/305015299.md)
- [FDA Investigates Cancer Risk Associated With Novartis' Zolgensma Gene Therapy](https://longbridge.com/en/news/304733391.md)
- [FDA probes tumour risk tied to Novartis gene therapy](https://longbridge.com/en/news/304705979.md)
- [Monte Rosa Therapeutics Q3 collaboration revenue jumps on Novartis milestone payment](https://longbridge.com/en/news/304453472.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**